	US 12,435,147 B2
	Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
Nabil Kerrouche, Le Rouret (FR); Keiko Hirokawa, Tokyo (JP); and Ryosuke Mihara, Tokyo (JP)
Assigned to Galderma Holding SA, Zug (CH); and Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed by GALDERMA HOLDING SA, La Tour-De-Peilz (CH); and Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed on Aug. 7, 2020, as Appl. No. 16/988,554.
Application 16/988,554 is a continuation of application No. PCT/IB2019/051051, filed on Feb. 8, 2019.
Claims priority of provisional application 62/628,714, filed on Feb. 9, 2018.
Prior Publication US 2020/0385476 A1, Dec. 10, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61P 17/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2866 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61P 17/00 (2018.01); A61K 39/395 (2013.01); A61K 2039/545 (2013.01)]

14 Claims

1. A method of selectively treating atopic dermatitis in a subject having one or more moderate to severe skin excoriations, the method comprising subcutaneously administering 30 mg or 60 mg of nemolizumab to the subject once every two weeks or once every four weeks, wherein the one or more moderate to severe skin excoriations have a score of at least 2 on the SCORAD scale.